A composition for inhibiting Malassezia and its application

Through compositions of components such as γ-undecide, pyroplatin, disodium EDTA and γ-nonolide, the resistance and side effects of existing anti-Malassezi drugs are solved, and the malase is achieved Effective inhibition and safe therapeutic effects of bacteria.

CN117771235BActive Publication Date: 2024-11-22完美(广东)日用品有限公司 +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311553671.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-21
Publication Date
2024-11-22
Estimated Expiration
2043-11-21

AI Technical Summary

Technical Problem

The existing anti-Malassezi drugs have problems with drug resistance, sensitization and side effects, and it is difficult to effectively inhibit Malassezi.

Method used

Provide a composition, including γ-undecide, pyroplatin, disodium EDTA and γ-nonolactone, etc., to form a composition with broad-spectrum anti-Malassezia activity through synergistic action and enhancement of activity. Applied in pharmaceutical and daily chemical products.

Benefits of technology

Effective inhibition of Malassezia is achieved, and a gentle and safe treatment plan is provided, suitable for the prevention and treatment of skin diseases caused by Malassezia, which significantly improves antibacterial activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004560313260000121
    Figure BDA0004560313260000121
  • Figure BDA0004560313260000131
    Figure BDA0004560313260000131
  • Figure BDA0004560313260000141
    Figure BDA0004560313260000141
Patent Text Reader

Abstract

The present invention relates to a composition for inhibiting Malassezia and its application in daily chemical products and medicines, belonging to the field of daily chemical products and medical technology. The composition of the present invention comprises cypress phenol, and also comprises at least one of γ-undecalactone, disodium EDTA, γ-nonalactone and lipoic acid. Cypress phenol and γ-undecalactone can synergistically inhibit Malassezia. Disodium EDTA can further enhance the anti-Malassezia activity of cypress phenol. γ-nonalactone and lipoic acid also have certain anti-Malassezia activity. In addition, the above-mentioned composition has a broad-spectrum anti-Malassezia effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of daily chemical products and medicines, and in particular to a composition for inhibiting Malassezia and application thereof in daily chemical products and medicines. Background Art

[0002] Malassezia is an important and understudied fungus in the human microbiome. Malassezia colonizes the scalp, face, chest, back, armpits, and groin areas of humans and animals where sebaceous glands are abundant and secretion is more active. Numerous studies have shown that Malassezia is associated with the pathogenesis of various skin diseases such as tinea versicolor, Malassezia folliculitis, seborrheic dermatitis / dandruff, atopic dermatitis, and psoriasis.

[0003] Topical antifungal drugs are the most commonly used treatment for Malassezia-related diseases, including azoles, polyenes, etc. In addition, zinc pyrithione and sulfonamide drugs can also be used as alternative drugs. At present, in the field of medicine, the most widely used anti-Malassezia drugs are azoles such as ketoconazole; in the field of daily chemical products, widely used anti-Malassezia drugs include zinc pyrithione, climbazole, piroctone olamine salt, and hexamidine di(hydroxyethylsulfonic acid) salt. Studies have found that Malassezia has developed resistance to Western medicines such as ketoconazole, and there are problems such as allergenicity and side effects. It is urgent to develop new anti-Malassezia drugs. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a mild and safe composition that can significantly inhibit Malassezia, and to apply the composition to the field of medical technology or daily chemical products.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is:

[0006] In a first aspect, the present invention provides an anti-Malassezia composition, which comprises at least one of γ-undecalactone and disodium EDTA and hinokitiol.

[0007] The inventors of the present invention have found that hinokitiol itself has strong anti-Malassezia activity, and γ-undecalactone itself also has certain anti-Malassezia activity. The combination of γ-undecalactone and hinokitiol has a synergistic anti-Malassezia effect. Disodium EDTA itself does not have anti-Malassezia activity, but the addition of disodium EDTA can enhance the anti-Malassezia activity of hinokitiol.

[0008] As a preferred embodiment of the composition of the present invention, the mass ratio of γ-undecalactone to hinokitiol is in the range of (1.99-31.89):1.

[0009] The inventors of the present invention have found that within the above-mentioned mass ratio range of γ-undecalactone to hinokitiol, γ-undecalactone and hinokitiol have a synergistic inhibitory effect on Malassezia.

[0010] As a preferred embodiment of the composition of the present invention, the molar ratio of the cypress phenol to disodium EDTA is 1:(0.5-4).

[0011] The inventors of the present invention have found that within the above-mentioned molar ratio range of hinokitiol and disodium EDTA, disodium EDTA can enhance the anti-Malassezia activity of hinokitiol.

[0012] As a preferred embodiment of the composition of the present invention, the composition further comprises at least one of γ-nonalactone and lipoic acid.

[0013] The inventors of the present invention have found that γ-nonalactone and lipoic acid have certain anti-Malassezia activity. The combination of γ-nonalactone and hinokitiol has an additive effect on the inhibition of Malassezia.

[0014] Another object of the present invention is to provide the use of the above composition in the preparation of products for preventing or treating skin diseases caused by Malassezia.

[0015] As a preferred embodiment of the present invention, in the application of the above composition, the skin diseases include but are not limited to tinea versicolor, Malassezia folliculitis, seborrheic dermatitis / dandruff, atopic dermatitis, psoriasis or psoriasis.

[0016] As a preferred embodiment of the present invention, in the application of the above-mentioned composition, the product is a medicine or a pharmaceutical preparation, and the pharmaceutical preparation includes but is not limited to tablets, capsules, granules, pills, oral liquids, emulsions, dry suspensions, dry extracts or injections and other common pharmaceutical internal dosage forms and lotions, ointments, patches, emulsions or sprays and other external dosage forms.

[0017] As a preferred embodiment of the present invention, in the application of the above-mentioned composition, the product is a daily chemical product, and the daily chemical product includes but is not limited to shampoo, shower gel, ointment, cream, lotion, hand soap or soap.

[0018] As a preferred embodiment of the present invention, in the application of the above-mentioned composition, the Malassezia includes but is not limited to Malassezia furfur CBS1878, Malassezia globosa CBS7966, Malassezia slophii CBS7956, Malassezia sympodialis CBS7222 or Malassezia obtusiformis CBS7876.

[0019] Another object of the present invention is to provide a daily chemical product or medicine comprising the above composition, wherein the mass percentage of the composition to the total weight of the daily chemical product or medicine is 0.0012%-20%.

[0020] As a preferred embodiment of the present invention, the mass percentage of the composition to the total weight of the daily chemical product or medicine is 0.05%-8%.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] (1) The present invention uses two or more of hinokitiol, γ-undecalactone, disodium EDTA, γ-nonalactone and lipoic acid in combination to obtain a composition with strong anti-Malassezia activity. Among them, hinokitiol and γ-undecalactone have a synergistic anti-Malassezia effect, and the addition of disodium EDTA can enhance the anti-Malassezia effect of hinokitiol. γ-nonalactone and hinokitiol have an additive effect on the inhibitory activity of Malassezia. Lipoic acid also has a certain anti-Malassezia effect.

[0023] (2) The composition of the present invention comprising cypermethrin and γ-undecalactone has a broad-spectrum anti-Malassezia effect, and the Malassezia includes but is not limited to Malassezia furfur CBS1878, Malassezia globosa CBS7966, Malassezia slophii CBS7956, Malassezia sympodioides CBS7222 or Malassezia obtusiformis CBS7876.

[0024] (3) The present invention provides a variety of mild and safe compositions with good anti-Malassezia activity, and these compositions are applied in the field of medical technology or daily chemical products, and are used in the preparation of products for preventing or treating skin diseases caused by Malassezia.

[0025] (4) The present invention also provides several daily chemical products or medicines comprising the above composition. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Attached Figure 1 After different treatments (0.5-2.5)×10 6 cfu / mL of Malassezia cultured at 30°C for 24 hours. Columns 1-10 of rows AD and EH were added with ten gradients of cypress phenol diluted by the two-fold dilution method. The cypress phenol used in columns 1-10 of rows AD was purchased from Hubei Guangao Biotechnology Co., Ltd., and the cypress phenol used in columns 1-10 of rows EH was purchased from Fulcon Flavors & Fragrances Co., Ltd. Column 11 is the growth control, and column 12 is the blank control. DETAILED DESCRIPTION

[0027] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of them. Based on the embodiments of the present invention, other embodiments obtained by technicians in this field without creative work are all within the scope of protection of the present invention. The test methods used in the embodiments are conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, can be reagents and materials obtained from commercial channels. Unless otherwise specified, the same parameter in each embodiment has the same value. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and cannot be understood as limitations on the present invention.

[0028] Test materials: Malassezia furfur (M. furfur, ATCC44344) was purchased from Guangdong Provincial Microbiological Culture Collection Center. Except for the cypress phenol used in columns 1-10 of rows EH in Example 2, which was purchased from Fulkang Flavors and Fragrances Co., Ltd., the cypress phenol used in columns 1-10 of rows AD in other examples and Example 2 was purchased from Hubei Guangao Biotechnology Co., Ltd. γ-undecalactone and γ-nonalactone were purchased from Guangzhou Daily Chemical Co., Ltd. The positive control zinc pyrithione (ZPT) was purchased from Guangzhou Tianci High-tech Materials Co., Ltd. The positive control piroctone ethanolamine salt (OCT) was purchased from Jining Spike New Materials Co., Ltd.

[0029] Example 1

[0030] This example tests the anti-Malassezia activity of four monomeric compounds, namely, cypermethrin, γ-undecalactone, γ-nonalactone and lipoic acid.

[0031] 1. The test method is as follows:

[0032] (1) Preparation of modified Dixon medium: Add 36 g malt extract powder, 6 g peptone, 20 g ox bile powder, 2 g glycerol, 2 g oleic acid, 10 g agar and 10 g Tween 40 to 1 L water, adjust the pH to 6.0 ± 0.2 (25°C), sterilize at 121°C for 15 min, cool to 50-60°C, pour into a plate, wait for it to solidify, and place in a 4°C refrigerator for later use.

[0033] Preparation of Leeming-Notman (LN) medium: Add 32g Leeming-Notman medium base and 15g agar powder (solid medium with agar powder, liquid medium without agar powder) to 1L distilled water or deionized water, heat and boil to dissolve, and dispense into Erlenmeyer flasks. Add 1 bottle of olive oil (1.6mL) to every 80mL of the dispensed medium, sterilize at 115℃ for 20 minutes, cool to about 50℃, add 1 bottle of cycloheximide to every 80mL aseptically, shake well, and set aside.

[0034] (2) Activation of bacterial strains and preparation of bacterial suspension: Inoculate Malassezia furfur into the Leeming-Notman solid culture medium slant, culture at 28°C for 72 hours, and continue to subculture 1 to 2 times. Grind the bacteria on the slant finely with a disposable inoculation loop and add it to 10 mL of PBS and stir thoroughly. After absorbing the floating oil on the surface of the bacterial solution, transfer it to a sterile empty test tube, vortex and oscillate for 2 to 3 minutes and let it stand. After the undissolved colonies are precipitated, take the supernatant and transfer it to a new empty test tube for use. Spread count or plate count, dilute to 10 6 CFU / mL is reserved. CFU is colony forming unit.

[0035] (3) Preparation of drug solutions of different concentrations: The raw drug was completely dissolved in 15% sodium laureth sulfate (AES), and a certain amount of pure water was added to prepare drug solutions of different concentrations. AES was purchased from Hunan Lichen Aowei Industrial Co., Ltd.

[0036] (4) Determination of in vitro antibacterial activity using the Oxford cup diffusion method

[0037] The determination method is as follows: S1, prepare the modified Dixon solid medium, pour it into a plate, cool it down and solidify it for later use; S2, 7 CFU / mL of bacterial solution was diluted 200 times and added to the upper layer of the solidified culture medium described in step S1; the dilution method was to first add 1mL10 7 Add the bacterial solution with a concentration of CFU / mL to 19mL of water and mix well as A (diluted 20 times). Then mix 15g of the above A and 135g of modified Dixon solid medium (diluted 10 times). Use tweezers to gently place the sterile Oxford cup into the culture dish, and evenly place 2 Oxford cups in a horizontal plate. Pipette 200μL of the drug solution of a certain concentration in the above step (3) into the Oxford cup, and be careful not to overflow the Oxford cup. Set up 3 parallels for each group of sample solutions, and set up a blank control (PBS solution containing 15% AES) and a negative control (15% AES pure water solution). Culture at 32°C for 48 to 72h.

[0038] 2. Data measurement and result interpretation

[0039] Observe the results and measure the diameter of the inhibition zone (mm) with a vernier caliper. Perform three tests in parallel, and the results of the three tests shall prevail. The diameter of the inhibition zone shall be calculated based on the average of the three tests. According to the size of the inhibition zone, the sensitivity of Malassezia furfur to the drug was preliminarily judged. The results were determined in accordance with the standards of the National Committee for Clinical Trials Standards (NCCLS) of the United States: the diameter of the inhibition zone <8mm is insensitive, 8-13mm is low sensitivity, 13-19mm is moderately sensitive, and >19mm is highly sensitive. Those with antibacterial results in three repeated tests were judged as qualified, and no inhibition zone was produced in the negative control group, otherwise the test was invalid.

[0040] 3. Test results

[0041] The measurement results of the inhibition zone diameter of Malassezia furfur with different drug solutions are shown in Table 1 below.

[0042] Table 1

[0043] Liquid Concentration (mg / mL) Diameter of inhibition zone (mm) γ-Undecalactone 100 25.39 γ-Nonalactone 100 30.39 Lipoic Acid 100 41.53 Hinokitiol 100 >50.00 Positive control ZPT 10 27.4 Positive control OCT 10 20.4

[0044] As shown in Table 1, hinokitiol, γ-undecalactone, γ-nonalactone and lipoic acid have strong antibacterial activity against Malassezia, especially hinokitiol. In addition, no inhibition zone appeared in the negative control group (15% AES pure water solution).

[0045] Example 2

[0046] This example uses the urea broth two-fold dilution method to test the minimum inhibitory concentration MIC of cypress phenol, γ-undecalactone, γ-nonalactone and lipoic acid. The experimental method of this example refers to the M27 standard formulated by the Clinical and Laboratory Standards Institute (CLSI) - the reference method for antifungal susceptibility test of yeast broth dilution to conduct in vitro drug sensitivity test on Malassezia, and the culture medium selected is urea broth culture medium. Malassezia has urease activity, and the ammonia released by urea hydrolysis increases the pH of the system, and the phenol red indicator in the system turns the system from orange-yellow to pink. In order to provide the growth requirements of Malassezia, 0.5% Tween 40 is added to the culture medium.

[0047] 1. The test method is as follows

[0048] (1) Urea broth medium: Weigh 9.0 g of urea broth base in 1 L of distilled or deionized water, dissolve at a lukewarm temperature of about 50°C, dispense, and sterilize at 115°C for 20 minutes. When the above medium cools to below 50°C, add 1 tube of 40% urea solution (5 mL) to every 100 mL of the medium, mix well, dispense, and set aside. In order to meet the cultivation needs of Malassezia, add 1 tube of Tween 40 (1 mL) to every 200 mL of the medium.

[0049] (2) Preparation of drug solution and addition of samples

[0050] Preparation of drug solution: Dissolve hinokitiol, lipoic acid, γ-undecalactone, γ-nonalactone, and ZPT in DMSO, and dissolve OCT in 8% 305 thickening emulsifier aqueous solution. The maximum stock solution concentration of hinokitiol is 25 mg / mL, the maximum stock solution concentration of lipoic acid, γ-undecalactone, and γ-nonalactone is 100 mg / mL, and the maximum stock solution concentration of ZPT and OCT in the positive drug group is 6.25 mg / mL. Dilute 10 gradients with the corresponding solvent by double dilution method. Individual samples need to be determined according to the situation.

[0051] Drug sampling: In a 96-well plate, 4 μL of 10 gradient single drug solutions were added to wells 1-10, and the drug concentrations from well 1 to well 10 were from high to low, and then 96 μL of culture medium was added. 100 μL and 200 μL of urea broth culture medium were added to wells 11 and 12, respectively, as growth control and blank control, respectively. Four parallel controls were performed in each group, and the results were averaged. In a 96-well plate without bacterial solution, the concentration range of hinokitiol was 0.98-500 μg / mL, the concentration range of lipoic acid was 3.91-2000 μg / mL, and the concentration range of γ-undecalactone and γ-nonalactone was 7.81-4000 μg / mL.

[0052] (3) Preparation of bacterial solution and sample addition

[0053] Preparation of bacterial solution: After activating the Malassezia furfur slant strain, purify it by streaking on a plate, pick a single colony and culture it in LN liquid medium at 30°C for 72 hours to obtain a monoclonal bacterial solution, wash it twice with physiological saline, remove the residual LN medium, and then resuspend it in urea broth medium to adjust the OD 600 is about 0.15, and the number of viable bacteria on the plate is about 3×10 6 cfu / mL.

[0054] Add bacterial solution: add 100 μL of bacterial solution to each well in columns 1 to 11 of the above 96-well plate.

[0055] (4) Cultivation

[0056] The 96-well plate inoculated with bacterial solution and drug solution was incubated at 30°C for 24 hours.

[0057] 2. Data measurement and result interpretation

[0058] The positive wells showed a color change from yellow to red, and the lowest drug concentration at which the fungus was inhibited by 80% was taken as MIC.

[0059] 3. Test results

[0060] The minimum inhibitory concentration (MIC) of different drugs against Malassezia furfur determined by visual method is shown in Table 2 below.

[0061] Table 2

[0062] Drug Name MIC (μg / mL) Hinokitiol 3.91 Lipoic Acid 62.5 γ-Undecalactone 125 γ-Nonalactone 250 ZPT 1.95 OCT 15.63

[0063] The color of the culture medium after treatment with different concentrations of cypress phenol (two manufacturers) and the color results of the culture medium in the growth control group and the blank control group are shown in the attached figure. Figure 1 Attached Figure 1 The data show that the minimum inhibitory concentration (MIC) of cypress phenol purchased from two manufacturers under the culture conditions can be directly read by visual method, which is the concentration in the 8th column, that is, 3.91μg / mL, which is consistent with the results of the microplate reader. In addition, Table 2 shows that the MIC value of cypress phenol is relatively low, lower than the MIC value of the positive control OCT, and reaches the same order of magnitude as the MIC value of the positive control ZPT, which indicates that cypress phenol has good anti-Malassezia activity. In addition, lipoic acid, γ-undecalactone, and γ-nonalactone also show certain anti-Malassezia activity, which has certain research and application value.

[0064] Example 3

[0065] In this example, the checkerboard dilution method was used to perform a combined drug sensitivity test to determine the partial inhibitory concentration index (FICI) to evaluate the efficacy of the combined use of hinokitiol and other drugs.

[0066] 1. The test method is as follows:

[0067] (1) Preparation and addition of drug solution

[0068] Preparation of drug solution: The maximum stock solution concentration of cypress phenol is 12.5 mg / mL, the maximum stock solution concentration of lipoic acid is 100 mg / mL, and the maximum stock solution concentration of γ-undecalactone and γ-nonalactone is 2000 mg / mL.

[0069] Drug solution loading: The combination of cypress phenol and other natural products was loaded by the chessboard method, that is, in a 96-well plate, 96 μL of culture medium was added to the 1st to 10th columns of wells, and 2 μL of the multiple concentrations of the two drugs were added horizontally and vertically, respectively. The horizontal direction was a descending gradient of cypress phenol, with a total of 10 columns, and the vertical direction was a descending gradient of lipoic acid / γ-undecalactone / γ-nonalactone (one of them) with a total of 8 rows, so that the two drugs formed different combined drug concentrations in 80 wells, and the drug concentration decreased from the upper left to the lower right. 100 μL and 200 μL of liquid culture medium were added to the 11th and 12th columns of wells, respectively, as growth control and blank control. Cypress phenol was diluted by the two-fold dilution method for 10 gradients, and the other three natural products were diluted by the two-fold dilution method for 8 gradients.

[0070] (2) Preparation of bacterial solution and sample addition

[0071] The bacterial solution preparation and sample addition methods are the same as step (3) in the test method of Example 2.

[0072] (3) Cultivation

[0073] The 96-well plate inoculated with bacterial solution and drug solution was incubated at 30°C for 24 hours.

[0074] 2. Data measurement and result interpretation

[0075] The partial inhibitory concentration index (FICI) was used to evaluate the combined efficacy of hinokitiol and other drugs.

[0076] FICI is the sum of the MIC of each drug when used in combination divided by the quotient of each drug when used alone. That is, FICI = MIC (A drug in combination) / MIC (A drug alone) + MIC (B drug in combination) / MIC (B drug alone). MIC (A drug in combination) is the minimum inhibitory concentration of drug A in the drug combination when used in combination, MIC (A drug alone) is the minimum inhibitory concentration of drug A when used alone, MIC (B drug in combination) is the minimum inhibitory concentration of drug B in the drug combination when used in combination, and MIC (B drug alone) is the minimum inhibitory concentration of drug B when used alone. When FICI ≤ 0.5, it is a synergistic effect; when 0.5 < FICI ≤ 1, it is an additive effect; when 1 < FICI ≤ 2, it is an irrelevant effect; when FICI > 2, it is an antagonistic effect.

[0077] 3. Test results

[0078] The test results of the combined effects of cypress phenol and other three natural products are shown in Table 3.

[0079] Table 3

[0080] Combination medication FICI Combined Action Hinokitiol + Lipoic Acid 1.125 No effect Hinokitiol + γ-undecalactone 0.27 Synergy Hinokitiol + γ-nonalactone 0.75 Additive effect

[0081] As shown in Table 3, the three natural products (γ-undecalactone, γ-nonalactone, and lipoic acid) can respectively play a synergistic, additive, and unrelated (different mechanisms of action) role with hinokitiol, and their combination has high value. In particular, hinokitiol and γ-undecalactone have a synergistic anti-Malassezia effect.

[0082] In addition, the inventors found that when the final concentration of cypress phenol was 0.98 μg / mL and the final concentration of γ-undecalactone was 1.95, 3.91, 7.81, 15.63 or 31.25 μg / mL, there was a synergistic effect between the two (the mass ratio of γ-undecalactone to cypress phenol ranged from (1.99-31.89):1).

[0083] Example 4

[0084] In this embodiment, substances in the cosmetic raw material catalog are compounded, and metal complex modification research is carried out on effective natural products containing hydroxyl groups. Copper, iron, zinc, and magnesium salt complexes of cypress phenol are prepared, and complexes are made to study the anti-Malassezia effect of the cypress phenol modified complexes, in order to obtain new raw materials.

[0085] 1. Test methods

[0086] (1) "Hinoki phenol-Cu 2+ Preparation of the complex: Dissolve cypress phenol (0.0328 g, 0.2 mmol) and copper sulfate pentahydrate (0.05 g, 0.2 mmol) in 20 mL of methanol-ethanol-water (volume ratio: 2:1:

[0087] 1) The reaction was carried out at 50°C for 6 h in the solution. After standing overnight, the mixture was dried by rotation, dissolved in dichloromethane, washed twice with pure water, and the product layer was collected and dried to obtain 26.2 mg of a green oily product with a yield of 73%.

[0088] (2) "Hinoki phenol-Fe 2+ Preparation of the complex: Dissolve cypermethrin (0.0328 g, 0.2 mmol) and ferrous sulfate heptahydrate (0.0556 g, 0.2 mmol) in 20 mL of methanol-ethanol-water (volume ratio: 2:1:1) solution, react at 50 ° C for 6 h, stand overnight and then spin-dry, dissolve in dichloromethane, wash twice with pure water, collect the product layer, and dry to obtain 34.6 mg of a red oily product with a yield of 97%.

[0089] (3) "Hinoki phenol-Zn 2+ Preparation of the complex: Dissolve cypermethrin (0.0328 g, 0.2 mmol) and zinc sulfate heptahydrate (0.0574 g, 0.2 mmol) in 20 mL of methanol-ethanol-water (volume ratio: 2:1:1) solution, react at 50 ° C for 6 h, stand overnight and then spin-dry, dissolve in dichloromethane, wash twice with pure water, collect the product layer, and dry to obtain 16.3 mg of light yellow oily product with a yield of 45%.

[0090] (4) "Hinoki phenol-Mg 2+ Preparation of the complex: Dissolve cypermethrin (0.0328 g, 0.2 mmol) and magnesium sulfate heptahydrate (0.0492 g, 0.2 mmol) in 20 mL of methanol, ethanol and water (volume ratio: 2:1:1) solution, react at 50 ° C for 6 h, stand overnight and then spin dry, dissolve in dichloromethane, wash twice with pure water, collect the product layer, and dry to obtain 25.2 mg of light yellow oily product with a yield of 74%.

[0091] (5) The "Hinoki phenol-Cu" prepared in steps (1) to (4) 2+ ","Hinoki phenol-Fe 2+","Hinoki phenol-Zn 2+ ","Hinoki phenol-Mg 2+ The anti-Malassezia activity of the complex was evaluated by the same method as described in Example 2. In a 96-well plate, cypress phenol-Cu 2+ , Hinokiol-Zn 2+ and hinokitiol-Mg 2+ The concentration range is 0.98-500 μg / mL, cypress phenol-Fe 2+ The concentration range is 7.81-4000μg / mL.

[0092] 2. Test results

[0093] The MIC test results of the cypress phenol metal salt complexes are shown in Table 4.

[0094] Table 4

[0095] Compound MIC (μg / mL) <![CDATA[Hinokitiol-Cu 2+ > 7.81 <![CDATA[Hinokitiol-Fe 2+ > — <![CDATA[Hinokitiol-Zn 2+ > 3.91 <![CDATA[Hinokitiol-Mg 2+ > 3.91 ZPT 1.95 OCT 15.63

[0096] As shown in Table 4, the modification of the complexes of cypress phenol and four ions cannot increase its antibacterial activity. On the contrary, the modified complexes with iron ions even lose their activity, indicating that iron ions seriously affect its activity. Thinking from another direction, removing the influence of iron ions may enhance the antibacterial activity of cypress phenol. Disodium EDTA, citric acid, and octanoylhydroxytungstate are all common iron ion chelators. The next step is to compound cypress phenol with these three chelators to eliminate the adverse effects of iron ions on its activity, in order to enhance its antibacterial activity.

[0097] Example 5

[0098] In this example, cypress phenol was compounded with three chelating agents (citric acid, octanoylhydroxytungstate, and disodium EDTA) to explore the antibacterial activity of the compounded chelating agents against Malassezia.

[0099] 1. The test method is as follows:

[0100] (1) Preparation and addition of drug solution

[0101] Preparation of drug solution: Dissolve hinokitiol, citric acid and octanoylhydroxytungstate in DMSO, and disodium EDTA in sterile water. Compound hinokitiol with three chelating agents in the molar ratio shown in Table 5, and dilute 10 gradients with the corresponding solvents by two-fold dilution method (when compounding hinokitiol and disodium EDTA, first dissolve them in their respective solvents into solutions of different concentrations, and then add 2μL hinokitiol and 2μL EDTA disodium to each well). The concentration of hinokitiol in the maximum concentration stock solution is 1.563mg / mL.

[0102] Drug solution addition: In a 96-well plate, add 4 μL of 10 gradient compound drug solutions to columns 1-10, and the drug concentrations in wells 1 to 10 are from high to low, then add 96 μL of culture medium, and add 100 μL and 200 μL of liquid culture medium to wells 11 and 12, respectively, as growth control and blank control, respectively. Four parallels are made at the same time, and the results are taken as the average of the four numbers. In the individual MIC value tests of EDTA disodium, citric acid and octanoylhydroxytungstate in a 96-well plate, the concentration range is 7.81-4000 μg / mL.

[0103] (2) Preparation of bacterial solution and addition of samples

[0104] The preparation of bacterial solution and the method of adding samples are the same as the test method step (3) of Example 2 above.

[0105] (3) Cultivation

[0106] The culture method is the same as step (4) of the test method in Example 2 above.

[0107] 2. Test results

[0108] After cypress phenol was compounded with three chelating agents, the MIC test results of cypress phenol and chelating agents against Malassezia are shown in Table 5.

[0109] Table 5

[0110]

[0111]

[0112] It can be seen from the data in Table 5 that disodium EDTA itself does not have antibacterial activity, but its combination with cypress phenol in a molar ratio of (0.5-4):1 can significantly reduce the MIC value of cypress phenol and enhance the anti-Malassezia activity of cypress phenol, so that the MIC value of cypress phenol is further reduced to 1.95 μg / mL, reaching the same level as ZPT.

[0113] Example 6

[0114] This example investigates the antibacterial activity of three compound prescriptions against five species of Malassezia.

[0115] 1. Test methods

[0116] (1) Preparation of compound formula: Based on the above research, combined with the limited information in the 2021 version of the catalog of used cosmetic raw materials, cypress phenol: disodium EDTA: γ-undecalactone: γ-nonalactone: lipoic acid were compounded in a mass ratio of 1:2:2.5:2.5:0.4 to obtain composition 1; cypress phenol: disodium EDTA: γ-undecalactone were compounded in a mass ratio of 1:2:2.5 to obtain composition 2; cypress phenol: disodium EDTA: γ-undecalactone were compounded in a mass ratio of 1:1:31 to obtain composition 3. 8% of composition 1, composition 2 and composition 3 were added to a 15% AES aqueous solution, and ten gradients were diluted by the two-fold dilution method for testing.

[0117] (2) Minimum inhibitory concentration test of the composition against five species of Malassezia

[0118] The test method is the same as the test method described in Example 2 above.

[0119] 2. Test results

[0120] The concentration values ​​of cypermethrin under the minimum inhibitory conditions of compositions 1, 2 and 3 against five species of Malassezia are shown in Table 6 below.

[0121] Table 6

[0122]

[0123] Note: * refers to the concentration of cypress phenol under the minimum inhibitory condition of the composition.

[0124] It can be seen from Table 6 that compositions 1, 2 and 3 can exert a broad-spectrum anti-Malassezia effect.

[0125] Example 7

[0126] In order to further explore the antibacterial effect of the above raw material combination, 5 groups of shampoos were prepared in this example, and the anti-Malassezia effects of the 5 groups of shampoos were evaluated.

[0127] 1. The test method is as follows:

[0128] (1) Preparation of shampoo

[0129] Preparation of Shampoo 1-3: 0.4 parts of cypermethrin, 0.8 parts of disodium EDTA, 0.16 parts of lipoic acid, 1 part of γ-undecalactone, and 1 part of γ-nonalactone were dissolved in a solution of 10 parts of Tween 20 and 20 parts of water to form Shampoo Additive 1. Add additive 1 at a ratio of 0.5% to 2,000 parts of shampoo stock solution (water, sodium lauryl sulfate, sodium laureth sulfate, sodium chloride, ethylene glycol distearate, polydimethylsiloxane, zinc carbonate flavor, cocamidopropyl betaine, hydrochloric acid, sodium benzoate, guar hydroxypropyltrimethylammonium chloride, basic magnesium carbonate, propylene glycol), stir, filter, and obtain shampoo 1 (the mass percentage of the composition to the total content of the shampoo is about 0.05%); add additive 1 at a ratio of 5% to 2,000 parts of shampoo, stir, filter, and obtain shampoo 2 (the mass percentage of the composition to the total content of the shampoo is about 0.5%); add additive 1 at a ratio of 25% to 2,000 parts of shampoo, stir, filter, and obtain shampoo 3 (the mass percentage of the composition to the total content of the shampoo is about 2.5%).

[0130] Preparation of Shampoo 4: 0.4 parts of hinokitiol, 0.16 parts of lipoic acid, 1 part of γ-undecalactone, and 1 part of γ-nonalactone were dissolved in a solution of 10 parts of Tween 20 and 20 parts of water to form Shampoo Additive 2. Additive 2 was added to 2,000 parts of shampoo at 1.5%, stirred, and filtered to obtain Shampoo 4.

[0131] Preparation of Shampoo 5: 0.4 parts of hinokitiol, 1 part of γ-undecalactone, and 1 part of γ-nonalactone were dissolved in a solution of 10 parts of Tween 20 and 20 parts of water to form Shampoo Additive 3. Additive 3 was added to 2,000 parts of shampoo at 1.5%, stirred, and filtered to obtain Shampoo 5.

[0132] (2) MIC test of five groups of shampoos against Malassezia furfur

[0133] The test method is the same as the test method described in Example 2 above.

[0134] 2. Test results

[0135] In the MIC test of shampoo against Malassezia furfur, the concentration data of cypermethrin at the minimum inhibitory concentration are shown in Table 7.

[0136] Table 7

[0137] Shampoo Concentration of hinokitiol at the minimum inhibitory concentration of the composition (μg / mL) Shampoo 1 1.33 Shampoo 2 1.33 Shampoo 3 1.33 Shampoo 4 2.66 Shampoo 5 5.32

[0138] As shown in Table 7, the minimum inhibitory concentration of cypress phenol is affected by disodium EDTA and lipoic acid in the composition. Disodium EDTA and lipoic acid should not be removed, which once again confirms the synergistic effect between the raw materials. In addition, as shown in Table 7, the composition can exert an excellent antibacterial effect when the addition amount is 0.05%. In order to ensure that the shampoo has better antibacterial properties, the shampoo 2 formula is selected. After expanding production, 1000 bottles are canned according to 500mL per bottle.

[0139] Example 8

[0140] In order to further explore the antibacterial effect of the above raw material combination, 5 groups of creams were prepared in this example, and the anti-Malassezia effects of the 5 groups of creams were evaluated.

[0141] 1. The test method is as follows:

[0142] (1) Preparation of cream

[0143] Components and masses of cream 1: 5.04 parts of the composition (0.6 parts of cypermethrin, 1.2 parts of disodium EDTA, 0.24 parts of lipoic acid, 1.5 parts of γ-undecalactone, 1.5 parts of γ-nonalactone), 60 parts of octadecyl alcohol, 80 parts of liquid paraffin, 30 parts of monoglyceride, 40 parts of white vaseline, 15 parts of ethoxymonoglyceride, 2 parts of butylated hydroxytoluene (BHT), 50 parts of glycerol, 1.0 part of ethylparaben, and the remainder is distilled water. The total mass of the cream is 1000 parts.

[0144] Components and masses of cream 2: 10.08 parts of composition (1.2 parts of cypermethrin, 2.4 parts of disodium EDTA, 0.48 parts of lipoic acid, 3 parts of γ-undecalactone, 3 parts of γ-nonalactone), 60 parts of octadecyl alcohol, 80 parts of liquid paraffin, 30 parts of monoglyceride, 40 parts of white vaseline, 15 parts of ethoxymonoglyceride, 2 parts of BHT, 50 parts of glycerol, 1.0 part of ethylparaben, and the balance is distilled water. The total mass of the cream is 1000 parts.

[0145] Components and masses of cream 3: 20.16 parts of composition (2.4 parts of cypermethrin, 4.8 parts of disodium EDTA, 0.96 parts of lipoic acid, 6 parts of γ-undecalactone, 6 parts of γ-nonalactone), 60 parts of octadecyl alcohol, 80 parts of liquid paraffin, 30 parts of monoglyceride, 40 parts of white vaseline, 15 parts of ethoxymonoglyceride, 2 parts of BHT, 50 parts of glycerol, 1.0 part of ethylparaben, and the balance is distilled water. The total mass of the cream is 1000 parts.

[0146] Components and masses of cream 4: 7.68 parts of composition (1.2 parts of cypermethrin, 0.48 parts of lipoic acid, 3 parts of γ-undecalactone, 3 parts of γ-nonalactone), 60 parts of octadecyl alcohol, 80 parts of liquid paraffin, 30 parts of monoglyceride, 40 parts of white vaseline, 15 parts of ethoxymonoglyceride, 2 parts of BHT, 50 parts of glycerol, 1.0 part of ethylparaben, and the balance is distilled water. The total mass of the cream is 1000 parts.

[0147] Components and mass of cream 5: 7.2 parts of the composition (1.2 parts of cypermethrin, 3 parts of γ-undecalactone, 3 parts of γ-nonalactone), 60 parts of octadecyl alcohol, 80 parts of liquid paraffin, 30 parts of monoglyceride, 40 parts of white vaseline, 15 parts of ethoxymonoglyceride, 2 parts of BHT, 50 parts of glycerol, 1.0 part of ethylparaben, and the balance is distilled water. The total mass of the cream is 1000 parts.

[0148] Preparation method of cream 1-5: Take octadecyl alcohol, liquid paraffin, monoglyceride, white vaseline and ethoxy monoglyceride, heat to 80°C, add BHT, dissolve and filter to obtain the oil phase. Separately take ethyl paraben and add to glycerin and heat until completely dissolved, add distilled water and heat to a temperature close to that of the oil phase, slowly add the oil phase to the water phase, stir to 60°C, add the composition, and stir rapidly until condensed to obtain the cream.

[0149] (2) The MIC test was performed directly using the cream as the maximum concentration according to a test method similar to that of Example 2.

[0150] 2. Test results

[0151] In the MIC test of the cream against Malassezia furfur, the concentration data of hinokitiol at the minimum inhibitory concentration are shown in Table 8.

[0152] Table 8

[0153] Cream Concentration value of hinokitiol at the minimum inhibitory concentration of the composition (μg / mL) Cream 1 1.33 Cream 2 1.33 Cream 3 1.33 Cream 4 2.66 Cream 5 5.32

[0154] As can be seen from Table 8, the antibacterial concentration of cypermethrin is affected by disodium EDTA and lipoic acid in the composition, and disodium EDTA and lipoic acid should not be removed, which once again confirms that the raw materials have a synergistic effect. This result is consistent with Example 7. In order to ensure that the cream has a better antibacterial effect, the cream formulation 2 is selected.

[0155] Example 9

[0156] In this example, a tablet containing the above composition was prepared.

[0157] 1. The preparation method is as follows

[0158] Take a total of 10.08g of the composition (1.2g of hinokitiol, 2.4g of disodium EDTA, 0.48g of lipoic acid, 3g of γ-undecalactone, and 3g of γ-nonalactone), mix it with 100g of starch, add 10g of 10% starch slurry to make a soft material, add 1g of magnesium stearate and 10g of dry starch, mix well, and press into 1000 tablets. Each tablet contains a total of 10mg of the composition, and the mass percentage of the composition in the total weight of the tablet is 7.69%.

[0159] 2. Antibacterial test

[0160] Preparation of stock solution: Take 3 tablets, crush them, add 5 mL DMSO, ultrasonicate for 20 min, centrifuge, and take the supernatant.

[0161] The MIC test was performed according to a similar test method as in Example 2.

[0162] 3. Test results:

[0163] The concentration of hinokitiol in the stock solution was about 0.71 mg / mL. The concentration of hinokitiol in the tablet solution of the composition was 1.39 μg / mL at the minimum inhibitory concentration.

[0164] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for resisting Malassezia, It is characterized in that The composition is γ-undecalactone, disodium EDTA and hinokitiol; The mass ratio of γ-undecalactone to hinokitiol is in the range of (1.99-31.89):1; The molar ratio of the cypress phenol to disodium EDTA is 1:(0.5-4).

2. Use of the composition according to claim 1 in the preparation of products for preventing or treating skin diseases caused by Malassezia.

3. The use according to claim 2, It is characterized in that The skin disease is tinea versicolor, Malassezia folliculitis, seborrheic dermatitis, dandruff, atopic dermatitis, psoriasis or psoriasis; and / or, the product is a medicine or a pharmaceutical preparation, and the pharmaceutical preparation is a tablet, capsule, granule, pill, oral solution, emulsion, dry suspension, dry extract, injection, lotion, ointment, patch, emulsion or spray; And / or, the products are daily chemical products, and the daily chemical products are shampoo, shower gel, ointment, cream, lotion, hand soap or soap; And / or, the Malassezia comprises at least one of Malassezia furfur CBS1878, Malassezia globosa CBS7966, Malassezia slophii CBS7956, Malassezia sympodialis CBS7222, and Malassezia obtusiformis CBS7876.

4. A daily chemical product or medicine, It is characterized in that The daily chemical product or medicine comprises the composition according to claim 1.

5. The daily chemical product or medicine according to claim 4, It is characterized in that The weight of the composition is 0.0012%-20% of the total weight of the daily chemical product or medicine.

6. The daily chemical product or medicine according to claim 5, It is characterized in that The weight of the composition is 0.05%-8% of the total weight of the daily chemical product or medicine.